With the approach of an aging society, the number of inconveniences caused by aging or potential lesions has also increased, and the growth of related markets has increased. Westin Medical Technology and National Taiwan University Hospital for Exoskeleton on the 7th The robots held a signing press conference, attended by Weichuang Chief Financial Officer Lin Fuqian, Wistron Technology Chief and Wistron Medical General Manager Huang Jundong, and held a signing ceremony with the Vice President of the National Taiwan University, Yu Zhongren. It is understood that Wistron is currently in the medical big data. Organizing, artificial intelligence image judgment and long-term investment in the area of in vitro detection with molecular diagnostics, and exoskeleton robots will be new development areas. It is understood that due to the aging of the population, it is estimated that by 2050 the Asian elderly population will approach 1 billion people. Previously, Wistron had invested NT$1.2 billion to establish Wistron Biotech Investment Holdings, actively investing in biotechnology and medical-related fields, and established Wistron Medical Technology to collaborate with robot company Bionik Laboratories to develop and commercialize lower body limb mobility assistive devices. In cooperation with Fubao Technology, it will invest in the development of mobile robotics. At present, the Fubao-developed product will soon land in Japan. For sale, Fubao Technology signed a contract with USCI Japan in 2017. Lin Fuqian stated that the technology industry should not be absent from the robotics industry. Wistron selection is a way to make more contribution to human beings. This part needs medical care, new innovation, and industrial cooperation. In order to make products practical and commercial, cooperation with NTU is not just for clinical purposes. This is the first case of cooperation between Wistron and NTU. It will be more than just a project for the future, and we hope to achieve more profound development. With the assistance of NTU's medical institutions, we will develop and improve the introduction of second and third generation exoskeleton robots. At the same time, Wistron will provide research and development resources and operational resources including cooperation with Taiwan, the United States, Japan, and some Israeli institutions and new innovative teams. All of them will make more profound development with NTU. Yu Zhongren stated that the medical technology industry is the future trend. Apart from biotechnology, information applications and industrial needs are high. Taiwan University Hospital has invested in rehabilitation medicine for a long time, with special expertise and unique experience. , Look forward to the prospects after the signing of the cooperation between the two parties. This cooperation plan provides Wistron Medical with intelligent exoskeleton medical equipment. Chen Wen, Director of Rehabilitation Department, National Taiwan University Hospital A clinical team led by Lin Fang Yu, a physiotherapy technician, conducts clinical trials and studies with user experience to achieve the maximum synergy of research and application development. Integrating technology with medical care to provide high-quality, humane medical services in response to the general public Requirement. It is understood that in order to quickly establish clinical data, Wistron Medical also collaborates with Cathay Hospital to conduct clinical trials of intelligent powered lower extremity exoskeleton robots. It is expected to obtain medical certification from 2019 to 2020. However, in Canada, Japan, India and other places Due to different laws and regulations, some regions will be expected to start selling before the end of 2018. As for the selling price, Wistron Medical emphasizes that it will rely on Wistron’s accumulated experience in the information industry to reduce product R&D costs and achieve optimal goals. .
